Project Grant R21AG098360
- Federal Grant Award Summary The University of Pittsburgh received a $2,003,400 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2029. This award funds research to characterize white matter injury in Alzheimer's disease (AD) using a novel neuroimaging methodology called Unhealthy White Matter Connectivity (UWMC). The research investigates risk factors for and consequences of white...
- Federal Grant Award Summary The University of Pittsburgh received a $664,619 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period January 1, 2026 through December 31, 2030. The award supports research to develop multiscale computational models of age-specific neurometabolic coupling—the relationship between neuronal activity and metabolic processes in the brain. This research addresses a critical gap in understanding metabolic...
- Federal Project Grant Award Summary The University of Pennsylvania received a $6.72 million project grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2029. This project grant funds the development and characterization of short RNA therapeutics designed to combat TDP-43 proteinopathy, a pathological hallmark present in multiple neurodegenerative disorders including amyotrophic lateral...
- Federal Grant Award Summary The National Institute on Aging (part of the Aging Research program, CFDA 93.866) awarded the University of Southern California a $3.35 million Project Grant effective September 15, 2025, with a completion date of August 31, 2029. This research award supports investigations into regulated cGAS activation in herpes simplex virus-1 (HSV-1)-associated neuropathogenesis and its connection to Alzheimer's disease and related dementia. The project will employ de novo...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Johns Hopkins University $1,083,046 under the Aging Research program (CFDA 93.866) for a two-year project period extending from August 1, 2025 through July 31, 2027. This Project Grant funds the development of novel adeno-associated virus (AAV) vectors designed for selective targeting of oligodendrocyte precursor cells (OPCs) in the central nervous system. The research addresses a critical knowledge gap regarding OPC...
- Federal Grant Award Summary The University of South Florida received a $3.3 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective September 1, 2025 through August 31, 2029. This award supports the development of novel peptidomimetic biomaterials designed to inhibit amyloid-beta (Aβ42) aggregation as a therapeutic intervention for Alzheimer's disease. The primary deliverables include the rational design and synthesis of structurally...
- Federal Grant Award Summary The University of Pittsburgh received a $437,250 Project Grant award dated August 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) from the National Institutes of Health Office of the Director. This R21 award will support research investigating the role of CD4 T helper 1 (TH1) cells and T central memory (TCM) cells in driving neuroinflammation associated with HIV-associated neurocognitive disorders (HAND). The research will be conducted through...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of Pittsburgh a $453,932 Project Grant under the Aging Research program (CFDA 93.866) for the period February 1, 2026 through January 31, 2028. The award supports the development and pilot testing of a narrative video game intervention designed to improve advance care planning (ACP) among persons living with dementia and their care partners. The intervention addresses cognitive biases that impair...
- Federal Grant Award Summary The University of Pennsylvania received a $487,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 15, 2025, with completion targeted for July 31, 2030. The project will develop the first in vivo CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screening platform to identify genetic regulators of microglial phagocytosis...
- Federal Grant Award Summary The University of Pittsburgh received a $430,170 Project Grant awarded on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) administered by the National Institute of Allergy and Infectious Diseases. This award funds research through June 30, 2027, to identify viral genetic determinants of Enterovirus D68 (EV-D68) neuropathogenesis using novel human spinal cord organoid models. The project will employ chimeric virus construction and...
The University of Pittsburgh received a $433,710 Project Grant from the National Institute on Aging (CFDA 93.866 – Aging Research program) awarded February 15, 2026, with completion scheduled for January 31, 2028. This award supports the development and refinement of epigenetically optimized, replication-defective herpes simplex virus (RDHSV) vectors designed as a gene therapy platform for treating Alzheimer's disease. The RDHSV vectors leverage a large payload capacity of approximately 35 kilobytes to deliver multiple therapeutic genes simultaneously, addressing the multifactorial nature of Alzheimer's disease through combination therapy approaches that target diverse pathological processes including amyloid-beta plaques, tau tangles, neuroinflammation, and neurodegeneration. Safety is achieved through removal of immediate early genes encoding infected cell proteins, while long-term transgene expression is ensured through viral and cellular insulators that prevent host silencing of therapeutic genes. The research initiative recognizes limitations of current monotherapies for Alzheimer's disease, including recently approved monoclonal antibodies that clear amyloid plaques but face challenges such as amyloid-related imaging abnormalities and limited overall effectiveness. By developing an advanced multigenic gene therapy delivery platform, this project aims to provide a more comprehensive treatment approach capable of simultaneously addressing the interconnected biochemical mechanisms driving disease progression across multiple pathways.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $433.7k | 2/5/26 |